Document is current
Any future updates will be listed below
-
Authors
Desai, Seemal R. https://orcid.org/0000-0002-3022-5169
Stein Gold, Linda
Cameron, Michael C.
Golant, Alexandra
Lewitt, G. Michael
Bruno, Matthew J.
Martin, George
Brown, Philip M.
Rubenstein, David S.
Butners, Victoria
Tallman, Anna M.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03956355 at ClinicalTrials.govnct03983980 at ClinicalTrials.govDocuments that mention this clinical trial
Rapid Improvements in Itch with Tapinarof Cream 1% Once Daily in Two Phase 3 Trials in Adults with Mild to Severe Plaque Psoriasis
https://doi.org/10.1007/s13555-023-01068-x
Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 Trials
https://doi.org/10.1007/s13555-023-01008-9
nct04053387 at ClinicalTrials.govDocuments that mention this clinical trial
Rapid Improvements in Itch with Tapinarof Cream 1% Once Daily in Two Phase 3 Trials in Adults with Mild to Severe Plaque Psoriasis
https://doi.org/10.1007/s13555-023-01068-x
Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 Trials
https://doi.org/10.1007/s13555-023-01008-9
Documents that mention this clinical trial
Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 Trials
https://doi.org/10.1007/s13555-023-01008-9
- License Information
-
More Information
Article History
Received: 4 July 2023
Accepted: 7 August 2023
First Online: 11 September 2023
Declarations
:
: Seemal R. Desai has served as a consultant and investigator for Dermavant Sciences, Inc.; he also serves in multiple other leadership and industry roles unrelated to tapinarof cream 1%. Linda Stein Gold has served as a consultant, and/or has received payment for the development of educational presentations, and/or has received grants from Amgen, Arcutis, Bristol Myers Squibb, Dermavant Sciences, Inc., Eli Lilly, LEO Pharma, Ortho Dermatologics, Pfizer, and UCB Biopharma. Michael C. Cameron has served as a consultant, advisor, or speaker for AbbVie, Bristol Myers Squibb, Dermavant Sciences, Inc., Eli Lilly, EPI Health, Evelo Biosciences, Incyte, Journey Medical, LEO Pharma, Regeneron, and Ortho Pharmaceuticals. Alexandra Golant has received consulting or speaking fees from AbbVie, Amgen, Arcutis, Dermavant Sciences, Inc., Eli Lilly, Evelo Biosciences, Incyte, Janssen, LEO Pharma, Regeneron, and Sanofi. G. Michael Lewitt has served as a consultant, speaker, investigator, or advisory board member and/or has received grants from AbbVie, Amgen, Inc., Bristol Myers Squibb, Dermavant Sciences, Inc., DermTech, Eli Lilly, Galderma, LEO Pharma, Janssen, Novan, Inc., Pfizer, Ortho Dermatologics, and UCB Biopharma. Matthew J. Bruno has served as a consultant and/or received payment for promotional presentations from AbbVie, Almirall, Bristol Myers Squibb, Dermavant Sciences, Inc., EPI Health, Journey Medical Corporation, Mayne Pharma, Medimetriks Pharmaceuticals, Pfizer, Regeneron/Sanofi-Genzyme, and Sun Pharmaceuticals. George Martin has served as a speaker and/or consultant and/or has been involved in scientific advisory boards for AbbVie, Almirall, Alumis, Bristol Myers Squibb, Celgene, Dermavant Sciences, Inc., DUSA/Sun, Eli Lilly, Evelo, Galderma, Horizon, Incyte, Janssen, LEO Pharma, Nobelpharma, Ortho/Bausch Health, Organogenesis, Pfizer, Trevi, and UCB Biopharma. Philip M. Brown, David S. Rubenstein, Victoria Butners, and Anna M. Tallman are employees of Dermavant Sciences, Inc., with stock options.
: The trials were conducted in accordance with Good Clinical Practice and the Declaration of Helsinki. Approval was obtained from the local ethics committee or institutional review board for each trial center. All the patients provided written informed consent and photographic release.
